The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

DNC000118     (1S)-3-(1-adamantyl)-1...

Synonyms: LS-173243, AC1L21MK, AC1Q3F7L, C20H27NO3.HCl, A77636, ...
This record was replaced with 64638.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of (1R)-3-(1-adamantyl)-1-(aminomethyl)isochroman-5,6-diol

  • These results show a lesser liability of A-86929 and A-77636 to reproduce dyskinesia in L-dopa-primed MPTP-lesioned subjects while maintaining effective antiparkinsonian activity and producing a more naturalistic motor response [1].
  • Upon reintroduction of L-dopa concurrently with continued A-77636 administration, dystonic, but virtually no choreic dyskinesias appeared and behaviour was once again free of stereotypy and hyperkinesis, contrasting dramatically with the presence of these behaviours along with abundant chorea when L-dopa is given alone [1].
  • In the present study, we show that the selective D1 agonist A77636 also induces orofacial dyskinesia when injected into the subthalamic nucleus of awake rats, thus confirming a role for D1 receptors in this effect [2].

Psychiatry related information on (1R)-3-(1-adamantyl)-1-(aminomethyl)isochroman-5,6-diol

  • RESULTS: A77636 (1.0 and 2.5 mg/kg, i.p.) produced a greater threshold-lowering effect in food-restricted than ad libitum fed rats but produced variable effects on locomotor activity with no difference between groups [3].

High impact information on (1R)-3-(1-adamantyl)-1-(aminomethyl)isochroman-5,6-diol

  • Both the selective D1-like agonist, A-77636, and the D2-like agonist, quinpirole, also induced Fos in orexin cells, suggesting that stimulation of either receptor subtype is sufficient to activate orexin neurons [4].
  • Comparison of interactions of D1-like agonists, SKF 81297, SKF 82958 and A-77636, with cocaine: locomotor activity and drug discrimination studies in rodents [5].
  • Because A-77636 consistently attenuated the present effects of cocaine, it may prove more useful than the others as a pharmacotherapy to treat cocaine abuse [5].
  • After a week of twice-daily L-dopa dosing, administration of the long-acting D1 agonist A-77636 initially dramatically enhanced locomotion and reproduced dyskinesia with prominent dystonia, but after repeated administration of A-77636, dyskinesia and in particular chorea, gradually disappeared [1].
  • Preincubation of rat striatal membranes with A-77636 resulted in a large decrease in D1 receptor binding, despite repeated washings, whereas A-81686 pretreatment caused only a small reduction in D1 receptor binding [6].

Chemical compound and disease context of (1R)-3-(1-adamantyl)-1-(aminomethyl)isochroman-5,6-diol


Biological context of (1R)-3-(1-adamantyl)-1-(aminomethyl)isochroman-5,6-diol

  • All three compounds dose-dependently increased the number of penile erections, with the full agonist A77636 showing a more pronounced effect with respect to the other two [8].
  • The results indicate that A-77636 exerted a suppressant effect on food intake, due principally to a reduction in meal size and duration [9].

Anatomical context of (1R)-3-(1-adamantyl)-1-(aminomethyl)isochroman-5,6-diol


Associations of (1R)-3-(1-adamantyl)-1-(aminomethyl)isochroman-5,6-diol with other chemical compounds

  • Treatment of intact rats with the full D(1) dopamine agonist A-77636 induced Fos-like immunoreactivity in the medial and, to a lesser extent, the lateral portions of the striatum [11].

Gene context of (1R)-3-(1-adamantyl)-1-(aminomethyl)isochroman-5,6-diol

  • We now explore the effects of acute versus repeated administration of A-77636 and the relative roles of D-1 and D-2 receptor involvement in its antiparkinsonian actions [12].

Analytical, diagnostic and therapeutic context of (1R)-3-(1-adamantyl)-1-(aminomethyl)isochroman-5,6-diol

  • Central treatments consisted of microinjections of quinpirole (0.3-10.0 micrograms/0.5 microliter) directly into the caudal NAcc, CP or cortex or A-77636 (30 micrograms/0.5 microliter) into the caudal NAcc or CP [13].


  1. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Pearce, R.K., Jackson, M., Britton, D.R., Shiosaki, K., Jenner, P., Marsden, C.D. Psychopharmacology (Berl.) (1999) [Pubmed]
  2. Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions. Mehta, A., Thermos, K., Chesselet, M.F. Synapse (2000) [Pubmed]
  3. Rewarding and locomotor-activating effects of direct dopamine receptor agonists are augmented by chronic food restriction in rats. Carr, K.D., Kim, G.Y., Cabeza de Vaca, S. Psychopharmacology (Berl.) (2001) [Pubmed]
  4. Dopaminergic regulation of orexin neurons. Bubser, M., Fadel, J.R., Jackson, L.L., Meador-Woodruff, J.H., Jing, D., Deutch, A.Y. Eur. J. Neurosci. (2005) [Pubmed]
  5. Comparison of interactions of D1-like agonists, SKF 81297, SKF 82958 and A-77636, with cocaine: locomotor activity and drug discrimination studies in rodents. Chausmer, A.L., Katz, J.L. Psychopharmacology (Berl.) (2002) [Pubmed]
  6. Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636. Lin, C.W., Bianchi, B.R., Miller, T.R., Stashko, M.A., Wang, S.S., Curzon, P., Bednarz, L., Asin, K.E., Britton, D.R. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  7. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Kebabian, J.W., Britton, D.R., DeNinno, M.P., Perner, R., Smith, L., Jenner, P., Schoenleber, R., Williams, M. Eur. J. Pharmacol. (1992) [Pubmed]
  8. Dopamine D1 receptor agonists induce penile erections in rats. D'Aquila, P.S., Panin, F., Cossu, M., Peana, A.T., Serra, G. Eur. J. Pharmacol. (2003) [Pubmed]
  9. The anorectic effect of the selective dopamine D1-receptor agonist A-77636 determined by meal pattern analysis in free-feeding rats. Cooper, S.J., Al-Naser, H.A., Clifton, P.G. Eur. J. Pharmacol. (2006) [Pubmed]
  10. D1 dopamine receptors mediate neuroleptic-induced Fos expression in the islands of Calleja. Wirtshafter, D. Synapse (1998) [Pubmed]
  11. Comparative effects of scopolamine and quinpirole on the striatal fos expression induced by stimulation of D(1) dopamine receptors in the rat. Wirtshafter, D., Asin, K.E. Brain Res. (2001) [Pubmed]
  12. The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration. Smith, L.A., Jackson, M.J., Al-Barghouthy, G., Jenner, P. Journal of neural transmission (Vienna, Austria : 1996) (2002) [Pubmed]
  13. The effects of systemic and intracerebral injections of D1 and D2 agonists on brain stimulation reward. Ranaldi, R., Beninger, R.J. Brain Res. (1994) [Pubmed]
WikiGenes - Universities